Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
This list highlights altcoins with clear real-world use cases and tangible value, helping readers prioritize projects with practical impact.
24,805 articlesA major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Choosing when to claim Social Security isn’t just about age—it’s a strategy. Delaying benefits can lead to a larger l...
A routine auto theft can spiral into a cross-state investigation. This article breaks down what happened, the financi...
A focused look at a nuclear energy stock with small modular reactors (SMRs) at the center. Learn the potential upside...
When SpaceX first hit the public markets, traders expected spectacle but not necessarily sustainability. A surprising...
Quantum computing is still in its early innings, and Rigetti Computing sits at a pivotal crossroads. This article bre...
A high-profile Ethereum MEV bot suffered a dramatic $7.5 million loss, prompting talk of legal action. This article u...
A midrange, budget-friendly Apple device could broaden the company’s market and boost services revenue. This guide an...
A surprise move puts a legendary director in the spotlight as a leading actor. This Tangled Up in Blue project offers...
CrowdStrike has shown momentum, but the stock carries risk. Here’s why I’m skeptical and how investors can approach c...
SpaceX saw a sharp weekly decline as bond-market concerns weighed on sentiment. Analysts flag Starlink expansion, AI ...
Microsoft’s stock has faced a rough start this year, stirring questions about value, timing, and long-term fit. This ...